Skip to main content
. 2008 Dec 12;64(2):361–369. doi: 10.1007/s00280-008-0882-8

Table 4.

Toxicity results

Toxicity gradea Grade 1 Grade 2 Grade 3 Grade 4
No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%)
Hematological toxicity
 Anemia 1 (2.6) 7 (18.4) 0 0
 Leucocytopenia 1 (2.6) 6 (15.8) 0 0
 Neutropenia 11 (28.9) 6 (15.8) 2 (5.3) 0
 Thrombocytopenia 2 (5.3) 0 0 0
 Elevated ALP 17 (44.7) 2 (5.3) 0 0
 Elevated AST 14 (36.8) 3 (7.9) 0 0
 Elevated ALT 12 (31.6) 1 (2.6) 0 0
 Elevated γ-GTP 8 (21.1) 3 (7.9) 2 (5.3) 0
 Elevated T-Bil 11 (28.9) 5 (13.2) 0 0
 Elevated creatinine 1 (2.6) 0 0 0
 Hypercalcemia 16 (42.1) 1 (2.6) 0 0
 Hypoalbuminemia 12 (31.6) 0 0 0
Nonhematological toxicity
 Hand–foot syndrome 16 (42.1) 5 (13.2) 3 (7.9) 0
 Mucositis 11 (28.9) 0 0 0
 Nausea 8 (21.1) 0 0 0
 Vomiting 4 (10.5) 0 0 0
 Diarrhea 7 (18.4) 1 (2.6) 1 (2.6) 0
 Constipation 0 0 1 (2.6) 0
 Abdominal pain 1 (2.6) 0 0 0
 Edema 3 (7.9) 0 0 0
 Rash 1 (2.6) 0 0 0
 Hyperpigmentation 5 (13.2) 0 0 0
 Pruritus 1 (2.6) 0 0 0
 Injection site reaction 1 (2.6) 0 0 0
 Nail changes 1 (2.6) 1 (2.6) 0 0
 Ulceration 1 (2.6) 0 0 0
 Cervical pain 1 (2.6) 0 0 0
 Chest pain 2 (5.3) 0 0 0
 Cough 2 (5.3) 1 (2.6) 0 0
 Sputum 0 1 (2.6) 0 0
 Dyspnea 0 1 (2.6) 0 0
 Fever 3 (7.9) 1 (2.6) 0 0
 Fatigue 10 (26.3) 2 (5.3) 0 0
 Appetite loss 2 (5.3) 1 (2.6) 0 0
 Weight loss 0 1 (2.6) 0 0
 Headache 5 (13.2) 0 0 0
 Dizziness 1 (2.6) 0 0 0
 Voice changes 1 (2.6) 0 0 0
 Impaired motor function 4 (10.5) 0 0 0
 Photophobia 0 1 (2.6) 0 0
 Cataract 0 1 (2.6) 0 0
 Back pain 1 (2.6) 0 0 0
 Urinary retention 1 (2.6) 0 0 0
 Pain on urination 1 (2.6) 0 0 0

aAccording to National Cancer institute common Toxicity Criteria